Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis - PubMed (original) (raw)

Review

Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis

R Beresford et al. Drugs. 1987 Jan.

Abstract

Haloperidol decanoate is a depot preparation of haloperidol, a commonly used butyrophenone derivative with antipsychotic activity. Haloperidol decanoate has no intrinsic activity: its pharmacodynamic actions are those of haloperidol--primarily that of central antidopamine activity. The monthly administered depot formulation has several clinical and practical advantages over oral haloperidol: better compliance and more predictable absorption; more controlled plasma concentrations; fewer extrapyramidal side effects; less frequent reminders of condition; and reduced medical workload. In open and controlled studies, haloperidol decanoate has produced adequate maintenance or improvement of the condition of patients with psychoses (mainly schizophrenia) when an abrupt change from orally administered haloperidol or other antipsychotic drugs has been instituted. Limited comparative studies indicate that the depot and oral forms of haloperidol are equally effective, and that haloperidol decanoate is at least as effective as depot forms of fluphenazine, pipothiazine, flupenthixol and perphenazine in controlling the symptoms of psychosis. Extrapyramidal side effects and the need for concomitant anti-Parkinsonian drugs may be a problem, but may be less frequent than with oral haloperidol or other depot antipsychotics. Thus, haloperidol decanoate offers a useful alternative in the treatment of psychoses to orally administered haloperidol or to other depot antipsychotic drugs.

PubMed Disclaimer

Cited by

Pharmacokinetics of haloperidol.
Froemming JS, Lam YW, Jann MW, Davis CM. Froemming JS, et al. Clin Pharmacokinet. 1989 Dec;17(6):396-423. doi: 10.2165/00003088-198917060-00004. Clin Pharmacokinet. 1989. PMID: 2689040 Review.
Pre-dosing antibody levels and efficacy of thrombolytic drugs containing streptokinase.
Gemmill JD, Hogg KJ, Dunn FG, Rae AP, Hillis WS. Gemmill JD, et al. Br Heart J. 1994 Sep;72(3):222-5. doi: 10.1136/hrt.72.3.222. Br Heart J. 1994. PMID: 7946770 Free PMC article.
Characteristics of oral movements in rats during and after chronic haloperidol and fluphenazine administration.
See RE, Levin ED, Ellison GD. See RE, et al. Psychopharmacology (Berl). 1988;94(3):421-7. doi: 10.1007/BF00174701. Psychopharmacology (Berl). 1988. PMID: 3128820
Intermittent and continuous haloperidol regimens produce different types of oral dyskinesias in rats.
See RE, Ellison G. See RE, et al. Psychopharmacology (Berl). 1990;100(3):404-12. doi: 10.1007/BF02244615. Psychopharmacology (Berl). 1990. PMID: 2315437
Depot antipsychotic drugs. Place in therapy.
Davis JM, Matalon L, Watanabe MD, Blake L, Metalon L [corrected to Matalon L]. Davis JM, et al. Drugs. 1994 May;47(5):741-73. doi: 10.2165/00003495-199447050-00004. Drugs. 1994. PMID: 7520856 Review.

References

1. Acta Psychiatr Scand. 1984 Feb;69(2):175-6 - PubMed
1. J Clin Psychopharmacol. 1986 Feb;6(1 Suppl):30S-37S - PubMed
1. Int J Clin Pharmacol Ther Toxicol. 1980 Jul;18(7):324-7 - PubMed
1. Nature. 1984 May 24-30;309(5966):347-9 - PubMed
1. Pharmacopsychiatry. 1985 May;18(3):240-5 - PubMed

Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis - PubMed (original) (raw)